These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31818448)

  • 21. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How to deal ugly twins, LDL-cholesterol and lipoprotein (a)].
    Piťha J
    Vnitr Lek; 2016; 62(11):903-907. PubMed ID: 28128577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 27. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
    Moriarty PM; Gray JV; Gorby LK
    J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
    Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
    Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization.
    Zafrir B; Egbaria A; Stein N; Elis A; Saliba W
    J Clin Lipidol; 2021; 15(1):202-211.e2. PubMed ID: 33243717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
    Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
    Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
    J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
    Boffa MB; Koschinsky ML
    Curr Opin Lipidol; 2019 Dec; 30(6):428-437. PubMed ID: 31577611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.